IZERVAY™, is the Second Treatment Approved by the FDA for Geographic Atrophy 

IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc.  announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]

Prevent Blindness Accepting Applications For New ASPECT Program

The application period is now open for all who wish to participate in the ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program at Prevent Blindness. Individuals with vision impairment or blindness are welcome to participate, as well as allies (i.e. parents or guardians, care partners, nonprofit representatives, multidisciplinary clinicians, eye care providers, [Read More]

Loss of Confidence

A Message to the AMD Community from Dan Roberts 1998 I have experienced a symptom of vision loss, and I wonder if anyone else can relate to it. It is not physical, and it is not emotional. This is a much more subtle psychological symptom which seems to lurk in the background and affect nearly [Read More]